1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company; and
2. General corporate purposes.
...
ganic chemistry, biotechnology and complex injectables. We have a globalleadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volumeterms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormoneAPIs. (Source: F&S Report) We are the only Indian and global company to have a presence across the top 10corticosteroid and steroidal-hormone APIs in Fiscal 2025, (Source: F&S Report) demonstrating the depth of ourportfolio. We manufacture these products using fermentation and multi-step complex chemical reactions. With over30 years of industry experience, we have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 intoan industrial-scale, backward-integrated platform with approvals from the United States Food and DrugAdministration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food andDrug Safety, Korea and other global organisations. We have leveraged our deep capabilities across organic chemistry,biotechnology, and complex injectables to operate as a contract development and manufacturing organisation(“CDMO”) variably for specialty pharmaceutical and nutraceutical companies globally, offering products andservices across the three platforms in which we also manufacture our own products. As of June 30, 2025, we had twooperational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67metric tonnes (“MT”) and fermentation capacity of 300 kilolitres (“KL”). Further, as of the date of this Draft RedHerring Prospectus, we have newly commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complexinjectables capacity of 20 million vials per annum, enabling us to function as a vertically integrated ‘microbe-topharmacy’and ‘farm-to-pharmacy’ platform with cost-efficient operations. Our biotechnology facilities are equippedwith fermenters of 5 KL, 35 KL and 100 KL, providing us flexibility in the scale of our operations. Further, we are inthe process of expanding our biologics capacity by adding a proposed dedicated 14 KL (comprising two reactors of 7KL each) fermentation capacity for biologics manufacturing in Ujjain. Read MoreMUFG Intime India Pvt Ltd.
Posted on Jan 17th
Capitalnumbers Infotech informs about resignation of senior management personnel
Posted on Jan 16th
KRM Ayurveda coming with IPO to raise Rs 77.49 crore
Posted on Jan 16th
Currency futures for January expiry trade weaker
Posted on Jan 16th
World Bank upwardly revises India’s GDP growth forecast to 7.2% for FY26 amid tax reforms
The issue size of Symbiotec Pharmalab Ltd. IPO is ₹0.00 - 0.00 crore.
The Symbiotec Pharmalab Ltd. IPO opens for subscription on and closes on .
The price range of Symbiotec Pharmalab Ltd. IPO is ₹0.00 to ₹0.00.
The lot size of Symbiotec Pharmalab Ltd. IPO is shares.
The registrar of Symbiotec Pharmalab Ltd. IPO is MUFG Intime India Pvt Ltd..
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.